Michael Rade, Markus Kreuz, Angelika Borkowetz, Ulrich Sommer, Conny Blumert, Susanne Füssel, Catharina Bertram, Dennis Löffler, Dominik J Otto, Livia A Wöller, Carolin Schimmelpfennig, Ulrike Köhl, Ann-Cathrin Gottschling, Pia Hönscheid, Gustavo B Baretton, Manfred Wirth, Christian Thomas, Friedemann Horn, Kristin Reiche
BACKGROUND: Clinical manifestation of prostate cancer (PCa) is highly variable. Aggressive tumors require radical treatment while clinically non-significant ones may be suitable for active surveillance. We previously developed the prognostic ProstaTrend RNA signature based on transcriptome-wide microarray and RNA-sequencing (RNA-Seq) analyses, primarily of prostatectomy specimens. An RNA-Seq study of formalin-fixed paraffin-embedded (FFPE) tumor biopsies has now allowed us to use this test as a basis for the development of a novel test that is applicable to FFPE biopsies as a tool for early routine PCa diagnostics...
February 1, 2024: Molecular Medicine